AstraZeneca PLC is set to give chase to GlaxoSmithKline PLC's Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab) in the severe eosinophilic asthma market, with a positive approval opinion from the European Medicines Agency's CHMP for its monoclonal antibody product benralizumab (as Fasenra) at its latest meeting this week.
AstraZeneca’s Benralizumab Asthma Chase Gets Underway
Watch out GlaxoSmithKline and Teva: AstraZeneca's benralizumab has wind in its sails following a EU CHMP positive opinion for severe asthma. Approval in the US is also expected by year end.
